Table 4.

Correlation between percentage change in anti-MCV and anti-CCP3 levels and changes in clinical, laboratory, and radiological variables. Only patients who were anti-MCV-positive and patients who were anti-CCP3-posi tive at baseline were included.

Variable	Change in Anti-MCV, % (n = 75)		Change in Anti-CCP, % (n = 71)
Variable	r	p	r	p
DAS-28	0.520	< 0.001^*	0.121	NS
ESR	0.263	0.03^*	0.054	NS
CRP	0.210	0.02^*	0.140	NS
TC/HDL-C	0.542	< 0.001^*	0.051	NS
LDL-C/HDL-C	0.592	< 0.001^*	0.121	NS
ApoA-I	0.551	< 0.001^*	0.054	NS
IL-6	0.542	< 0.001^*	0.131	NS
TNF-α	0.439	< 0.001^*	0.111	NS
HOMA-IR	0.432	< 0.001^*	0.063	NS
cIMT	0.441	< 0.001^*	0.055	NS

↵* Speaman rank correlation. Anti-MCV: anti-modified citrullinated vimentin; anti-CCP: anti-cyclic citrullinated peptide; DAS-28: Disease Activity Score for 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein chol esterol; apo: apolipoprotein; IL-6: interleukin 6; TNF-α: tumor necrosis factor-α; HOMA-IR: homeostasis model assessment for insulin resistance; cIMT: carotid intima-media thickness; NS: nonsignificant.